Risk for bleeding events is significantly affected by DOAC score in patients with atrial fibrillation who have received TAVR.

Compared with AS alone, coexisting ATTR-CA was associated with an increased risk of mortality (HR 1.3, 95% CI 1.1-1.4) in a ...

Medtronic CEO Geoff Martha discusses innovations such as pulse field ablation, renal denervation, DBS, TAVR, diabetes tech ...

The global cardiovascular devices market, valued at US$ 72.83 billion in 2023, is forecasted to grow at a robust CAGR of 7.3% ...

Edwards Lifesciences (EW) stock faces a downgrade at Wolfe due to concerns over its TAVR market prospects. Read more here.

Wolfe Research downgraded Edwards Lifesciences (EW) to Underperform from Peer Perform with a $60 price target The firm says its core ...

Doylestown Health’s Heart and Vascular Services team recently performed its 1,000th transcatheter aortic valve replacement at ...

Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...

The transcatheter aortic valve implantation gives patients the opportunity to continue their daily lives with minimal ...

The following is a summary of “Computed tomography derived predictors of left ventricular obstruction after TAVR,” published ...

An innovative heart procedure is changing the lives of patients with aortic valve disease. It's called transcatheter aortic valve replacement — or TAVR. We're learning more with BayCare.